Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O00585

UPID:
CCL21_HUMAN

ALTERNATIVE NAMES:
6Ckine; Beta-chemokine exodus-2; Secondary lymphoid-tissue chemokine; Small-inducible cytokine A21

ALTERNATIVE UPACC:
O00585; Q6ICR7

BACKGROUND:
The protein C-C motif chemokine 21, with aliases such as Small-inducible cytokine A21, plays a crucial role in the immune system's chemotaxis process. It binds to the atypical chemokine receptor ACKR4, mediating the recruitment of beta-arrestin to ACKR4, and exhibits a specific activity towards naive T-cells over other immune cells. This specificity suggests a targeted role in lymphocyte homing to secondary lymphoid organs.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of C-C motif chemokine 21 offers a promising avenue for the development of novel immunotherapies, leveraging its unique role in lymphocyte recruitment and immune regulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.